Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BBI-608 plus FOLFIRI versus FOLFIRI in previously treated metastatic colorectal cancer
NL-OMON55360Phase 3Active, not recruiting
- Sponsor
- Boston Biomedical, Inc
- Start
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of napabucasin in colorectal cancer (CRC) (2 arms), sponsored by Boston Biomedical, Inc. Primary endpoints: Overall survival in the general population and Overall survival in the pSTAT3-positive subpopulation. Started Feb 2017; status: active, not recruiting.
02
Drugs
napabucasin
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NL-OMON55360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55360.